ARS Pharmaceuticals (SPRY) EBIT (2020 - 2026)
ARS Pharmaceuticals (SPRY) posted EBIT of -$60.1 million for Q1 2026, down 45.05% sequentially from -$41.5 million in Q4 2025, and down 61.78% YoY from -$157.4 million in Q1 2025.
ARS Pharmaceuticals (SPRY) EBIT (2020 - 2026) Analysis & Trends
ARS Pharmaceuticals has reported EBIT for 7 years, with the latest figure at -$60.1 million in Q1 2026.
- Quarterly EBIT fell 61.78% year-over-year to -$60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$202.4 million (down 647.81% YoY) and the FY2025 annual result came in at -$179.4 million, down 5720.56% from the prior year.
- EBIT slipped to -$60.1 million in Q1 2026 per SPRY's latest filing, from -$41.5 million in the prior quarter.
- Over five years, EBIT peaked at $47.2 million in Q4 2024 and troughed at -$60.1 million in Q1 2026.
- A 5-year average of -$20.3 million and a median of -$18.0 million in 2023 frame the typical range for EBIT.
- The sharpest annual moves came in 2023 and 2024: EBIT plunged 224.76% in 2023, then jumped 561.54% in 2024.
- Over 5 years, EBIT stood at -$15.4 million in 2022, then surged by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plunged by 187.86% to -$41.5 million in 2025, then plunged by 45.05% to -$60.1 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$60.1 million, -$41.5 million, and -$53.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | ARS Pharmaceuticals | 561.88 Mn | 418.03 Mn | - | -61.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61.47 Mn |
| Mar 31, 2026 | -60.15 Mn |
| Dec 31, 2025 | -41.47 Mn |
| Sep 30, 2025 | -53.19 Mn |
| Jun 30, 2025 | -47.61 Mn |
| Mar 31, 2025 | -37.18 Mn |
| Dec 31, 2024 | 47.20 Mn |
| Sep 30, 2024 | -21.75 Mn |
| Jun 30, 2024 | -15.34 Mn |
| Mar 31, 2024 | -13.19 Mn |
| Dec 31, 2023 | -10.23 Mn |
| Sep 30, 2023 | -17.98 Mn |
| Jun 30, 2023 | -20.60 Mn |
| Mar 31, 2023 | -18.71 Mn |
| Dec 31, 2022 | -15.44 Mn |
| Sep 30, 2022 | -6.63 Mn |
| Jun 30, 2022 | -6.34 Mn |
| Mar 31, 2022 | -7.10 Mn |
| Dec 31, 2021 | 46.62 Mn |
| Sep 30, 2021 | -22.68 Mn |